טוען...
Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib
AIM: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). MATERIALS & METHODS: CECs in advanced HCC patients receiving sorafenib were counted...
שמור ב:
| הוצא לאור ב: | Hepat Oncol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Future Medicine Ltd
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095409/ https://ncbi.nlm.nih.gov/pubmed/30191052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0011 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|